Pfizer reignites the Parp biomarker debate
Talzenna scores in first-line prostate cancer irrespective of HRR status, but for now we only have Pfizer’s word for it.
FDA scrutiny now hits Parp inhibitors
A November adcom could decide whether Zejula will lose yet more ground to Lynparza.
Esmo 2022 movers – Kras backfires
Inhibition of Kras dominated Esmo, though probably not in the way some had hoped.
A bad day for Molecular Partners
Setbacks hit two of the Swiss biotech’s clinical-stage darpin projects in a single day.
Clovis equity investors overlook two elephants
Rubraca has scored in an all-comers, first-line ovarian cancer maintenance setting, but Clovis has bigger problems.
Asco-GU – prostate cancer Parps move to the front line
Lynparza squares off against Zejula while Rubraca and Talzenna wait in the wings, but should first-line use be restricted by biomarkers?
